Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Maintenance Therapy of Golidocitinib, a JAK1 Selective Inhibitor, in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy: Updates of the Phase 2 Study (JACKPOT26)

Jie Jin, Liling Zhang, Liqun Zou, Zengjun Li, Huijing Wu, Keshu Zhou, Lihua Qiu, Liping Su, Kaiyang Ding, Hui Zhou, Li Yu, Fei Li, Qing Xiao, Wenyu Li, Lie Lin, Erhua Wang, Lijia Chen, Qingqing Cai

Blood (2024) 144 (Supplement 1): 6368.

https://doi.org/10.1182/blood-2024-211891

Published: 2024

Journal Articles

The Treatment Pathways, Patient Characteristics and Outcomes in Patients with CD30-Expressing Lymphoma from China: A Multi-Center, Non-Interventional, Retrospective Study

Yi Miao, Wenyu Li, Kaiyang Ding, Fei Li, Xiaojing Yan, Xiaoxi Zhou, Caixia Li, Guohui Cui, Liqun Zou, Bing Xiu, Xiangxiang Zhou, Liansheng Zhang, Fuling Zhou, Hongmei Jing, Jianli Wang, Ziheng Guo, Jianyong Li

Blood (2024) 144 (Supplement 1): 6372.

https://doi.org/10.1182/blood-2024-201339

Published: 2024

Journal Articles

Clinical Characteristics and Initial Treatment Patterns of Mantle Cell Lymphoma in Btki Era: A Multi-Center Real-World Study in China

Mengya Cong, Junlei Jia, Zhanli Liang, Luming Cao, Huilai Zhang, Wenyu Li, Ou Bai, Haiwen Huang

Blood (2024) 144 (Supplement 1): 7813.

https://doi.org/10.1182/blood-2024-204982

Published: 2024

Journal Articles

Early Initiation of Calcineurin Inhibitor Induces CD8 + Transitory Exhausted-like and CD4 + Cytotoxic T Cells, Maintaining Responsiveness to PD-1 Blockade and Contributing to the Development of Chronic Gvhd after Post-Transplant Cyclophosphamide

Blood (2024) 144 (Supplement 1): 903.

https://doi.org/10.1182/blood-2024-197873

Published: 2024

Journal Articles

Ropeginterferon Alfa-2b Induces Apoptosis and Differentiation of Leukemia Stem Cells and Separates GVL Effects from Gvhd after Allogeneic Hematopoietic Cell Transplantation

Yumika Saito, Daigo Hashimoto, Keisuke Kojima, Shihori Tsukamoto, Tomoe Ichiki, Toru Miyajima, Wenyu Li, Shinpei Harada, Zixuan Zhang, Hajime Senjo, Yuta Hasegawa, Takahide Ara, Takanori Teshima

Blood (2024) 144 (Supplement 1): 902.

https://doi.org/10.1182/blood-2024-201237

Published: 2024

Journal Articles

Gvhd-Induced Inflammatory Memory in Intestinal Stem Cells Enhances IFN-γ-Induced Antigen Presentation and Apoptosis of Intestinal Epithelial Cells

Toru Miyajima, Daigo Hashimoto, Keisuke Kojima, Shihori Tsukamoto, Tomoe Ichiki, Yumika Saito, Wenyu Li, Zixuan Zhang, Shinpei Harada, Hajime Senjo, Yuki Yokoi, Yuta Hasegawa, Hiroyuki Ohigashi, Takahide Ara, Kiminori Nakamura, Koji Taniguchi, Takanori Teshima

Blood (2024) 144 (Supplement 1): 260.

https://doi.org/10.1182/blood-2024-202926

Published: 2024

Journal Articles

A Phase Ib Clinical Trial Investigating the Safety, Tolerability, and Pharmacokinetics of HX009，a Novel Bsab Dual Targeting PD-1 x CD47，in Patients with EBV + Non-Hodgkin Lymphoma (NHL)

Lin Gui, Keshu Zhou, Ting Liu, Yan Qin, Hongmei Jing, Wenyu Li, Yajun Li, Wenrong Huang, Zhen Wang, Xiuhua Sun, Quan Li, Faming Zhang, Henry Li, Lei Zhang, Peng Sun, Xinbao Gao, Yuankai Shi

Blood (2024) 144 (Supplement 1): 1741.

https://doi.org/10.1182/blood-2024-194771

Published: 2024

Journal Articles

Safety and Efficacy in Patients with Advanced Lymphomas from a Global Phase 1a/1b, First-in-Human Study of CS5001, a Novel Anti-ROR1 ADC

Blood (2024) 144 (Supplement 1): 1739.

https://doi.org/10.1182/blood-2024-192979

Published: 2024

Journal Articles

GVHD targets organoid-forming bile duct stem cells in a TGF-β–dependent manner

Yuta Hasegawa, Daigo Hashimoto, Zixuan Zhang, Toru Miyajima, Yumika Saito, Wenyu Li, Ryo Kikuchi, Hajime Senjo, Tomoko Sekiguchi, Takahiro Tateno, Xuanzhong Chen, Emi Yokoyama, Shuichiro Takahashi, Hiroyuki Ohigashi, Takahide Ara, Eiko Hayase, Isao Yokota, Takanori Teshima

Blood (2024) 144 (8): 904–913.

https://doi.org/10.1182/blood.2023023060

Published: 2024

Includes: Supplemental data

Journal Articles

Phase 2 Study of Golidocitinib, a JAK1 Selective Inhibitor, As Maintenance Therapy in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy (JACKPOT26)

Jie Jin, Qingqing Cai, Liling Zhang, Liqun Zou, Zengjun Li, Huijing Wu, Keshu Zhou, Lihua Qiu, Liping Su, Kaiyang Ding, Hui Zhou, Li Yu, Fei Li, Qing Xiao, Wenyu Li, Lie Lin, Erhua Wang, Lijia Chen

Blood (2023) 142 (Supplement 1): 4430.

https://doi.org/10.1182/blood-2023-185543

Published: 2023

Journal Articles

PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r ENKTL): Updates of the Phase Ib/II Scent Study

Gao Yan, Liling Zhang, Wenyu Li, Xu Wei, Ru Feng, Xue-Ping Li, Yu Chen, Huijing Wu, Xiaoxiao Wang, Bing Bai, Huiqiang Huang

Blood (2023) 142 (Supplement 1): 1689.

https://doi.org/10.1182/blood-2023-186252

Published: 2023

Journal Articles

A Phase Ib Open-Label Study of MRG001 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

Jun Zhu, Yuqin Song, Ye Guo, Keshu Zhou, Wenyu Li, Yu Yang, Qingqing Cai, Zhao Wang, Haiyan Yang

Blood (2023) 142 (Supplement 1): 3089.

https://doi.org/10.1182/blood-2023-189675

Published: 2023

Journal Articles

Delayed Initiation of Calcineurin Inhibitor Is Critical for Tolerance Induction By Posttransplant Cyclophosphamide

Hajime Senjo, Daigo Hashimoto, Satomi Okada, Shimpei I Kubota, Ayumu Ito, Takashi Tanaka, Yumika Saito, Toru Miyajima, Wenyu Li, Zixuan Zhang, Shinpei Harada, Yuta Hasegawa, Hiroyuki Ohigashi, Takahide Ara, Yoshinori Hasegawa, Yoshihiro Inamoto, Masaaki Murakami, Takahiro Fukuda, Takanori Teshima

Blood (2023) 142 (Supplement 1): 2041.

https://doi.org/10.1182/blood-2023-181560

Published: 2023

Journal Articles

Pre-Clinical Evaluation of a New-Generation Orally Bioavailable Dual Bcl-2/Bcl-Xl Inhibitor LP-118 in Mantle Cell Lymphoma

Ling-Ling Lee, Cong Zhu, Brianna Feldmeier, Yao Chen, Wenyu Li, Yu Chen, Stephen P. Anthony, Yue Shen, Fenlai Tan, Yi Chen, Bing Dai

Blood (2023) 142 (Supplement 1): 3640.

https://doi.org/10.1182/blood-2023-180190

Published: 2023

Journal Articles

Loncastuximab Tesirine Demonstrated Substantial Single-Agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2023) 142 (Supplement 1): 4469.

https://doi.org/10.1182/blood-2023-173645

Published: 2023

Journal Articles

Ferroptosis Inhibition Generates TCF-1 + CAR-T Cells with Enhanced Persistence and Cytotoxicity

Shinpei Harada, Daigo Hashimoto, Yumika Saito, Toru Miyajima, Wenyu Li, Hajime Senjo, Zixuan Zhang, Ryo Kikuchi, Masahiro Chiba, Hiroyuki Ohigashi, Takahide Ara, Masao Nakagawa, Takanori Teshima

Blood (2023) 142 (Supplement 1): 97.

https://doi.org/10.1182/blood-2023-179444

Published: 2023

Journal Articles

Golidocitinib in Treating Refractory or Relapsed Peripheral T- Cell Lymphoma: Full Analysis of the Multinational Pivotal Study Results (JACKPOT8)

Blood (2023) 142 (Supplement 1): 305.

https://doi.org/10.1182/blood-2023-172962

Published: 2023

Journal Articles

Clinical Characteristics and Outcomes of Follicular Lymphoma Patients with Extranodal Involvement: Analysis of a Series of 1090 Cases in China

Blood (2022) 140 (Supplement 1): 11979–11980.

https://doi.org/10.1182/blood-2022-162488

Published: 2022

Journal Articles

Disease Characteristics and Treatment Outcomes with HLX01: A Real-World Study in Patients with B-Cell Non-Hodgkin Lymphoma in China

Jun Ma, Li Zhiming, Wei Xu, Yao Liu, Weili Zhao, Zhihua Yao, Kaiyang Ding, Yudan Wu, Hong Liu, Wenyu Li, Yirong Jiang, Li'e Lin, Zhigang Peng, Zhimin Zhai

Blood (2022) 140 (Supplement 1): 12130–12132.

https://doi.org/10.1182/blood-2022-166137

Published: 2022

Journal Articles

Preliminary Safety and Efficacy of Relmacabtagene Autoleucel (relma-cel) in Adults with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL) in China

Zhitao Ying, Keshu Zhou, Lanfang Li, Wenyu Li, Su Yang, Yun Liu, Yongen Gu, Zisong Zhou, Alex Tian, Yuqin Song, Jun Zhu

Blood (2022) 140 (Supplement 1): 7470–7471.

https://doi.org/10.1182/blood-2022-164525

Published: 2022

NARROW

Maintenance Therapy of Golidocitinib, a JAK1 Selective Inhibitor, in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy: Updates of the Phase 2 Study (JACKPOT26)

The Treatment Pathways, Patient Characteristics and Outcomes in Patients with CD30-Expressing Lymphoma from China: A Multi-Center, Non-Interventional, Retrospective Study

Clinical Characteristics and Initial Treatment Patterns of Mantle Cell Lymphoma in Btki Era: A Multi-Center Real-World Study in China

Early Initiation of Calcineurin Inhibitor Induces CD8 + Transitory Exhausted-like and CD4 + Cytotoxic T Cells, Maintaining Responsiveness to PD-1 Blockade and Contributing to the Development of Chronic Gvhd after Post-Transplant Cyclophosphamide

Ropeginterferon Alfa-2b Induces Apoptosis and Differentiation of Leukemia Stem Cells and Separates GVL Effects from Gvhd after Allogeneic Hematopoietic Cell Transplantation

Gvhd-Induced Inflammatory Memory in Intestinal Stem Cells Enhances IFN-γ-Induced Antigen Presentation and Apoptosis of Intestinal Epithelial Cells

A Phase Ib Clinical Trial Investigating the Safety, Tolerability, and Pharmacokinetics of HX009，a Novel Bsab Dual Targeting PD-1 x CD47，in Patients with EBV + Non-Hodgkin Lymphoma (NHL)

Safety and Efficacy in Patients with Advanced Lymphomas from a Global Phase 1a/1b, First-in-Human Study of CS5001, a Novel Anti-ROR1 ADC

GVHD targets organoid-forming bile duct stem cells in a TGF-β–dependent manner

Phase 2 Study of Golidocitinib, a JAK1 Selective Inhibitor, As Maintenance Therapy in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy (JACKPOT26)

PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r ENKTL): Updates of the Phase Ib/II Scent Study

A Phase Ib Open-Label Study of MRG001 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

Delayed Initiation of Calcineurin Inhibitor Is Critical for Tolerance Induction By Posttransplant Cyclophosphamide

Pre-Clinical Evaluation of a New-Generation Orally Bioavailable Dual Bcl-2/Bcl-Xl Inhibitor LP-118 in Mantle Cell Lymphoma

Loncastuximab Tesirine Demonstrated Substantial Single-Agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Ferroptosis Inhibition Generates TCF-1 + CAR-T Cells with Enhanced Persistence and Cytotoxicity

Golidocitinib in Treating Refractory or Relapsed Peripheral T- Cell Lymphoma: Full Analysis of the Multinational Pivotal Study Results (JACKPOT8)

Clinical Characteristics and Outcomes of Follicular Lymphoma Patients with Extranodal Involvement: Analysis of a Series of 1090 Cases in China

Disease Characteristics and Treatment Outcomes with HLX01: A Real-World Study in Patients with B-Cell Non-Hodgkin Lymphoma in China

Preliminary Safety and Efficacy of Relmacabtagene Autoleucel (relma-cel) in Adults with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL) in China

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only